Nzme Limited

NZM

NZME Ltd. engages in publishing newspapers, magazines and operates radio stations. The firm operates through three segments: Audio, Publishing, and OneRoof. Audio segment consists of terrestrial radio stations, digital iHeartRadio, podcasts, and Radio brand websites. Publishing segment consists of print publications and digital news websites including nzherald.co.nz. and BusinessDesk. OneRoof segment comprises oneroof.co.nz and dedicated real estate print publications. OneRoof Herald Homes and OneRoof Local provide local property listings. Housing market trends, insights, and commentary, as well as tips that buyers, sellers, renters, and homeowners need, can also be found online at oneroof.co.nz. The Company’s subsidiaries include NZME Australia Pty Limited, NZME Educational Media Limited, NZME Holdings Limited, NZME Investments Limited, NZME Print Limited, NZME Publishing Limited, NZME Radio Investments Limited, and others.

New Zealand Coastal Seafoods Limited

NZS

New Zealand Coastal Seafoods Ltd. engages in processing, distributing and exporting seafood products and marine ingredients for supply, directly and through distributors, to customers, restaurants, seafood traders, supermarkets and other retailers in New Zealand, Australia and parts of Asia. The firm offers branded marine products, bulk marine products and nutraceutical ingredients. Its branded marine products include Ling Maw - Cooked in sauce and Dried Ling Maw. Its bulk marine products include Bulk Ling Fish Maw: Ling Maw White 60-75gram MSC, Bulk Ling Fish Maw: Ling Maw White 15-26gram MSC, Bulk Ling Fish Maw: Ling Maw Natural 60-75gram MSC, Bulk Ling Fish Maw: Ling Maw Natural 15-30gram MSC, Bulk Ling Fish Maw: Ling Maw Red 15-50gram MSC and Bulk Dried Greenshell Mussels. Its nutraceutical products include green lipped mussel powder, oyster powder and astaxanthin extract products, with the Company building a business case for extracting oils from marine ingredients. The firm has launched a flagship marine collagen product, produced using proprietary intellectual property techniques in processing and extraction.

Narryer Metals Limited

NYM

Narryer Metals Ltd. operates as a junior exploration company. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-04-14. The firm is engaged in exploring for pegmatite-hosted lithium in Canada with projects in areas: Yellowknife region, Northwest Territories, NW Ontario, and the James Bay Region, Quebec. Its focus is nickel-copper-platinum group element (Ni-Cu-PGE) sulphide deposits and Rare Earth Elements in Western Australia and Gawler Craton, South Australia. Three of the projects (Pontax East, Walrus Island and Le Moyne) are located in prospective Archean granite-greenstones of the James Bay region of Quebec. The Narryer Project covers the Narryer Terrane and is located along the western edge of the Archaean Yilgarn Craton. The Rocky Gully Project consist of two tenements over an area of 79 km2, located 43 km west of Mt Barker, Western Australia. The company also holds interest in several mineral claims comprising two lithium-tantalum exploration projects (Big Hill and Fran Projects) located in the Yellowknife Lithium Province, Canada.

Nyrada Inc.

NYR

Nyrada, Inc. is a pre-clinical stage, drug discovery, and development company, which engages in the business of specializing in novel small molecule drugs to treat cardiovascular and neurological diseases. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. The company is also developing new therapies.